Real Life Multicenter Comparison of 24-Month Outcomes of Anti-VEGF Therapy in Diabetic Macular Edema in Turkey: Ranibizumab vs. Aflibercept vs. Ranibizumab-Aflibercept Switch.

导出 OA

翻译打印收藏纠错

作者： Murat,Kucukevcilioglu ^[1] ; Yağmur Seda,Yeşiltaş ^[1] ; Ali Hakan,Durukan ^[1] ; Nurten,Unlu ^[2] ; Mehmet,Onen ^[3] ; Mehmet Numan,Alp ^[3] ; Defne,Kalayci ^[3] ; Mehmet Akif,Acar ^[3] ; Mehmet Ali,Sekeroglu ^[4] ; Mehmet,Citirik ^[4] ; Ayse Gul Kocak,Altintas ^[4] ; Dicle,Hazirolan ^[2] ; Pinar Cakar,Ozdal ^[4] ; Yasin,Toklu ^[3] ; Tolga,Bicer ^[5] ; Nagihan,Ugurlu ^[3] ; Ozlem,Budakoglu ^[4] ; Zeliha,Yazar ^[3] ; Nil Irem Ucgun,Zeki ^[3] ; Kurtulus,Serdar ^[6] ; Sibel,Doguizi ^[4] ; Yasemin Ozdamar,Erol ^[4] ; Cemile Ucgul,Atilgan ^[4] ; Mucella Arikan,Yorgun ^[3] ; Dilek Ozcelik,Soba ^[4] ; Nilufer,Berker ^[4] ; Ceyda,Baskan ^[3]

作者单位： Department of Ophthalmology, Gulhane School of Medicine, University of Health Sciences, 06010 Ankara, Türkiye. ^[1] Department of Ophthalmology, Ankara Training and Research Hospital, 06230 Ankara, Türkiye. ^[2] Department of Ophthalmology, Ankara City Hospital, 06800 Ankara, Türkiye. ^[3] Department of Ophthalmology, Ankara Ulucanlar Training and Research Hospital, 27300 Ankara, Türkiye. ^[4] Department of Ophthalmology, Dışkapı Yıldırım Beyazıt Training and Research Hospital, 06110 Ankara, Türkiye. ^[5] Augenland MVZ Goethaplatz, 60311 Frankfurt, Germany. ^[6]

关键词 anti-vascular endothelial growth factor (anti-VEGF)diabetic macular edema macular thickness real-world switch visual acuity